71 results on '"Stuschke, M"'
Search Results
2. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling
3. Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial
4. EP.07D.10 Deciphering Destiny: Is Curation of NSCLC Limited to Stage IA?
5. EP.07A.19 Impact of Preoperative Pulmonary Function on Survival Following Lobectomy for Stage I and II Lung Cancer
6. P1.06C.05 The Impact of Lymphovascular Invasion as Prognostic Factor on Long-Term Survival in More Than 3500 Resected NSCLC Patients
7. MA08.05 Lung Cancer in Young Adults is Associated with Advanced Disease at Diagnosis and Increased Frequency of Targetable Mutations
8. 1457P Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome
9. Robust Radiosensitization by Combined Treatment of Cancer Cells with Talazoparib and Polθ Inhibitors
10. MO-0952 A multicentric retrospective analysis of the potential synergy between radiotherapy and CAR T-cells
11. Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer
12. 963P Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315
13. 671P Postoperative chemoradiation in combination with cetuximab followed by 6-months cetuximab maintenance in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence
14. EP04.02-007 First Comprehensive Lung Cancer Long-Term Survivorship Program- Competing Risks
15. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb):a pilot phase I/II trial
16. 1162P Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany - AIO-TRK-0315
17. 922P Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting
18. Superior Prognostic Performance of an Immunohistochemistry Trained DNA-Methylation Based PD-L1 Score in Patients with HNSCC Treated with Radiochemotherapy: A Multicenter Study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
19. P2.01-94 Advanced Age and High Modified Glasgow Prognostic Score Are Associated with Increased Complications After Pneumonectomy
20. A Methylome Classifier Identifies Patients at Risk for Locoregional Recurrence after Adjuvant Radiochemotherapy in HPV-DNA negative HNSCC: a Multicenter Trial of the German Cancer Consortium- Radiation Oncology Group (DKTK-ROG)
21. Prognostic Value of Metabolic Tumor Volume after Induction Chemotherapy in Stage IIIA/B Non-Small-Cell Lung Cancer – Secondary Analysis of a Randomized Phase 3 Trial
22. OC-0496 Deep-learning based estimation of locoregional control for patients with locally advanced HNSCC
23. OC-0390 TCGA molecular subclassification is prognostic for LRC of HNSCC after postoperative RCTx
24. 26 Overcoming the limitations of lung cancer radiotherapy by targeting the CD73/adenosine immune checkpoint
25. OC-0588: Validation of the reRT risk score (RRRS) in glioma patients: A multicenter DKTK/ROG analysis
26. OC-0508: Identification of tumour sub-volumes for improved radiomic risk modelling in locally advanced HNSCC
27. OC-0493: Pretreatment metabolic volume in PET: Prognostic in lung cancer? German ESPATUE randomised phase3trial
28. OC-0324: Immune contexture in SCCHN and outcome after chemoradiotherapy in an uni- and multicentric cohort
29. OC-0276: Combining different genomic signatures to improve the prognostic power for LRC after PORT-C in HNSCC
30. MS 16.04 Future Direction of Immuno-Radiotherapy
31. PO-0619: Comparison of a nanoString and RNA microarray gene signature predicting LRC after PORT-C in HNSCC
32. SP-0010: The gains to be made by combined modality treatment in NSCLC: setting the scene of new possibilities
33. Assessment of conformal stereotactic radiosurgery and radiotherapy (CSRS/T)
34. PO-0674: Brain relapses in stage III NSCLC after multimodality treatment: prognostic factors from a randomised trial
35. PO-0670: Decrease in tumor SUVmax during definitive or neoadjuvant RT/CT is a prognostic factor in LAD lung cancer
36. Definitive Hyperfractionated Accelerated (AHF) Radiochemotherapy (CRT) Versus Neoadjuvant AHF-CRT and Surgery (S) for Patients (pts) With Operable Stage IIIA(N2)/Selected IIIB Non-small-Cell Lung Cancer (NSCLC) Following Induction Chemotherapy (IND-C): Results From a Multicenter Phase III Study
37. PO-0660: Neoadjuvant TPF-based RT/CT for oral cavity carcinomas increases pathologic remissions and survival
38. SP-0018: Oesophageal cancer
39. EP-1175: Accelerated chemo-irradiation in patients with contralateral central or mediastinal relapse after pneumonectomy
40. Postpneumonectomy Radical Accelerated (Re-)irradiation and Concurrent Chemotherapy for Patients With Contralateral Central Lung Cancer Relapses
41. Accelerated Hyperfractionated Radiation Therapy Within Trimodality Therapy Concepts for Stage IIIa/b Non-small Cell Lung Cancer: Markedly Higher Rate of Pathologic Complete Remissions Than With Conventionally Fractionated Radiochemotherapy
42. 1118 Potential Role of Lymphocytes During DNA Damage-induced Pneumopathy
43. 955 ADDRESSING BARRIERS TO PATIENT ACCRUAL IN CLINICAL TRIALS: LESSONS FROM THE EORTC PROSTATE CANCER TRIAL 22043-30041
44. 1254 poster MVCT IMAGE GUIDANCE IN HELICAL TOMOTHERAPY FOR PATIENTS WITH VERTEBRAL TUMORS: IMAGE RESOLUTION AND INTEROBSERVER VARIABILITY
45. Is PET/CT Response of Prognostic Value in Intensified Definitive Chemoradiation for Locally Advanced Non–small Cell Lung Cancer?
46. PET-CT for Patients (pts) Selection within a Multimodality Treatment Protocol (CTx + CTx/RTx ± S) in Pts with Locally Advanced (LAD) Non-Small Cell Lung Cancer (NSCLC)(Inoperable Stage IIIA/Selected IIIB)
47. The role of chemoradiotherapy in the treatment of stage III non-small-cell lung cancer
48. Preoperative chemoradiation approaches to locally advanced non-small-cell lung cancer: one man’s pride, another man’s burden?
49. Randomized phase III trial in locally advanced squamous cell carcinoma of the esophagus: Neoadjuvant radiochemotherapy followed by surgery vs. definitive radiochemotherapy
50. Accelerated hyperfractionated radiation therapy to 70.6 Gy plus 5-FU/MMC (C-HART) is more effective than HART to 77.6 Gy alone for locally advanced head and neck cancer. Four-year results of the German ARO 95-6 trial in 384 patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.